• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab eficacy

Research Project

Project/Area Number 15K10123
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Digestive surgery
Research InstitutionJapanese Foundation for Cancer Research

Principal Investigator

Wakatsuki Takeru  公益財団法人がん研究会, 有明病院 消化器内科, 副医長 (60443876)

Co-Investigator(Renkei-kenkyūsha) Yamamoto Noriko  公益財団法人がん研究会, がん研究所 病理部, 主任研究員 (10280629)
Mashima Tetsuo  公益財団法人がん研究会, がん化学療法センター 分子生物治療研究部, 主任研究員 (30311228)
Mori Seiichi  公益財団法人がん研究会, がんプレシジョン医療研究センター 次世代がん研究シーズ育成プロジェクト, プロジェクトリーダー (10334814)
Sano Takeshi  公益財団法人がん研究会, 有明病院, 副院長 (30215884)
Project Period (FY) 2015-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
KeywordsHER2 / Gastric cancer / HER2 heterogeneity / Trastuzumab / Biomarker / 胃癌 / HER2 heterigeneity / トラスツズマブ / 治療効果予測因子 / Heterogeneity / Gastric Cancer
Outline of Final Research Achievements

Intratumoral HER2 heterogeneity is ofted seen in gastric cancer. We evaluated an association between HER2 heterogeneity and trasutuzumab efficacy. We obtained new findings as follows; 1: When used surgical specimens, patients whose tumor homogeneously overexpressed HER2 protein had substantial benefit from trastuzumab. 2: When used biopsy specimens, similar results were obtained but its impact was modest compared with surgical specimens. 3: patients whose tumor heterogeneously overexpressed HER2 protein had modest benefit regardless types of tumor sample. HER2 heterogeneity in surgical specimens is useful biomarker as a positive predictor for anti-HER2 agents, while HER2 heterogeneity in biopsy specimens should be used as a negative predictor.

Report

(4 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • 2015 Research-status Report
  • Research Products

    (6 results)

All 2018 2017 2015

All Journal Article (1 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (5 results) (of which Int'l Joint Research: 2 results)

  • [Journal Article] Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer2018

    • Author(s)
      Wakatsuki Takeru、Yamamoto Noriko、Sano Takeshi、Chin Keisho、Kawachi Hiroshi、Takahari Daisuke、Ogura Mariko、Ichimura Takashi、Nakayama Izuma、Osumi Hiroki、Matsushima Tomohiro、Suenaga Mitsukuni、Shinozaki Eiji、Hiki Naoki、Ishikawa Yuichi、Yamaguchi Kensei
    • Journal Title

      Journal of Gastroenterology

      Volume: 印刷中 Issue: 11 Pages: 1186-1195

    • DOI

      10.1007/s00535-018-1464-0

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] HER2陽性胃癌における腫瘍内HER2 heterogeneityのtrastuzumab併用化学療法における意義2018

    • Author(s)
      若槻尊
    • Organizer
      日本消化器病学会総会
    • Related Report
      2017 Annual Research Report
  • [Presentation] Clinical significance of intratumoral HER2 heterogeneity (IHH) using endoscopic biopsy specimens in patients with HER2-positive gastric cancer (GC) who received T-mab-based chemotherapy.2017

    • Author(s)
      Shusuke Yagi
    • Organizer
      ASCO-GI 2017
    • Place of Presentation
      サンフランシスコ
    • Year and Date
      2017-01-19
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Presentation] Clinical significance of intratumoral HER2 heterogeneity using endoscopic biopsy specimens in patients with HER2 positive gastric cancer who received Trastuzumab based chemotherapy2017

    • Author(s)
      Shusuke Yagi
    • Organizer
      Gastrointestinal symposium
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] HER2陽性胃癌における生検検体を用いた腫瘍内不均一性の臨床的意義2017

    • Author(s)
      八木秀介
    • Organizer
      日本がん治療学会総会
    • Related Report
      2017 Annual Research Report
  • [Presentation] Clinical relevance of Intratumoral HER2 Heterogeneity on trastuzumab efficacy in HER2 Positive Gastric Cancer2015

    • Author(s)
      若槻尊
    • Organizer
      日本臨床腫瘍学会
    • Place of Presentation
      札幌
    • Year and Date
      2015-07-18
    • Related Report
      2015 Research-status Report

URL: 

Published: 2015-04-16   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi